The benefit of implementing a heart failure disease management program

D. J. Whellan, L. Gaulden, W. A. Gattis, B. Granger, S. D. Russell, M. A. Blazing, M. S. Cuffe, C. M. O'Connor

Research output: Contribution to journalArticle

Abstract

Background: To handle the increasing complexity of congestive heart failure (CHF) care, several new models for the care of patients with CHF have been developed to replace traditional strategies. We undertook this study to evaluate the potential benefit of implementing a CHF disease management program at a tertiary care center, particularly in terms of β-blocker use and cost to the health care system. Methods: After reviewing the literature regarding therapies and management strategies for patients with CHF, we developed the Duke Heart Failure Program. All enrolled patients had 1 of the following: recent CHF hospitalization, ejection fraction less than 20%, or symptoms consistent with New York Heart Association class III or IV. We compared preenrollment and postenrollment medication use and resource utilization. Results: We enrolled 117 patients from July 1998 to April 1999. Mean enrollment time was 4.7 months. β-Blocker use and dose significantly increased (52% vs 76% for β-blocker, P

Original languageEnglish (US)
Pages (from-to)2223-2228
Number of pages6
JournalArchives of Internal Medicine
Volume161
Issue number18
StatePublished - Oct 8 2001
Externally publishedYes

Fingerprint

Disease Management
Heart Diseases
Heart Failure
Tertiary Care Centers
Patient Care
Hospitalization
Delivery of Health Care
Costs and Cost Analysis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Whellan, D. J., Gaulden, L., Gattis, W. A., Granger, B., Russell, S. D., Blazing, M. A., ... O'Connor, C. M. (2001). The benefit of implementing a heart failure disease management program. Archives of Internal Medicine, 161(18), 2223-2228.

The benefit of implementing a heart failure disease management program. / Whellan, D. J.; Gaulden, L.; Gattis, W. A.; Granger, B.; Russell, S. D.; Blazing, M. A.; Cuffe, M. S.; O'Connor, C. M.

In: Archives of Internal Medicine, Vol. 161, No. 18, 08.10.2001, p. 2223-2228.

Research output: Contribution to journalArticle

Whellan, DJ, Gaulden, L, Gattis, WA, Granger, B, Russell, SD, Blazing, MA, Cuffe, MS & O'Connor, CM 2001, 'The benefit of implementing a heart failure disease management program', Archives of Internal Medicine, vol. 161, no. 18, pp. 2223-2228.
Whellan DJ, Gaulden L, Gattis WA, Granger B, Russell SD, Blazing MA et al. The benefit of implementing a heart failure disease management program. Archives of Internal Medicine. 2001 Oct 8;161(18):2223-2228.
Whellan, D. J. ; Gaulden, L. ; Gattis, W. A. ; Granger, B. ; Russell, S. D. ; Blazing, M. A. ; Cuffe, M. S. ; O'Connor, C. M. / The benefit of implementing a heart failure disease management program. In: Archives of Internal Medicine. 2001 ; Vol. 161, No. 18. pp. 2223-2228.
@article{1b777957267d44bc93f992b13c1a8029,
title = "The benefit of implementing a heart failure disease management program",
abstract = "Background: To handle the increasing complexity of congestive heart failure (CHF) care, several new models for the care of patients with CHF have been developed to replace traditional strategies. We undertook this study to evaluate the potential benefit of implementing a CHF disease management program at a tertiary care center, particularly in terms of β-blocker use and cost to the health care system. Methods: After reviewing the literature regarding therapies and management strategies for patients with CHF, we developed the Duke Heart Failure Program. All enrolled patients had 1 of the following: recent CHF hospitalization, ejection fraction less than 20{\%}, or symptoms consistent with New York Heart Association class III or IV. We compared preenrollment and postenrollment medication use and resource utilization. Results: We enrolled 117 patients from July 1998 to April 1999. Mean enrollment time was 4.7 months. β-Blocker use and dose significantly increased (52{\%} vs 76{\%} for β-blocker, P",
author = "Whellan, {D. J.} and L. Gaulden and Gattis, {W. A.} and B. Granger and Russell, {S. D.} and Blazing, {M. A.} and Cuffe, {M. S.} and O'Connor, {C. M.}",
year = "2001",
month = "10",
day = "8",
language = "English (US)",
volume = "161",
pages = "2223--2228",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "18",

}

TY - JOUR

T1 - The benefit of implementing a heart failure disease management program

AU - Whellan, D. J.

AU - Gaulden, L.

AU - Gattis, W. A.

AU - Granger, B.

AU - Russell, S. D.

AU - Blazing, M. A.

AU - Cuffe, M. S.

AU - O'Connor, C. M.

PY - 2001/10/8

Y1 - 2001/10/8

N2 - Background: To handle the increasing complexity of congestive heart failure (CHF) care, several new models for the care of patients with CHF have been developed to replace traditional strategies. We undertook this study to evaluate the potential benefit of implementing a CHF disease management program at a tertiary care center, particularly in terms of β-blocker use and cost to the health care system. Methods: After reviewing the literature regarding therapies and management strategies for patients with CHF, we developed the Duke Heart Failure Program. All enrolled patients had 1 of the following: recent CHF hospitalization, ejection fraction less than 20%, or symptoms consistent with New York Heart Association class III or IV. We compared preenrollment and postenrollment medication use and resource utilization. Results: We enrolled 117 patients from July 1998 to April 1999. Mean enrollment time was 4.7 months. β-Blocker use and dose significantly increased (52% vs 76% for β-blocker, P

AB - Background: To handle the increasing complexity of congestive heart failure (CHF) care, several new models for the care of patients with CHF have been developed to replace traditional strategies. We undertook this study to evaluate the potential benefit of implementing a CHF disease management program at a tertiary care center, particularly in terms of β-blocker use and cost to the health care system. Methods: After reviewing the literature regarding therapies and management strategies for patients with CHF, we developed the Duke Heart Failure Program. All enrolled patients had 1 of the following: recent CHF hospitalization, ejection fraction less than 20%, or symptoms consistent with New York Heart Association class III or IV. We compared preenrollment and postenrollment medication use and resource utilization. Results: We enrolled 117 patients from July 1998 to April 1999. Mean enrollment time was 4.7 months. β-Blocker use and dose significantly increased (52% vs 76% for β-blocker, P

UR - http://www.scopus.com/inward/record.url?scp=0035829092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035829092&partnerID=8YFLogxK

M3 - Article

C2 - 11575979

AN - SCOPUS:0035829092

VL - 161

SP - 2223

EP - 2228

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 18

ER -